Answer questions at the heart of your business, questions that in-house analysis may have left unchallenged.
An external industry perspective to complement your views on the market, competition, and your company's strategic direction.
Find out how a major global pharma gained an external perspective on market trends to support a key Executive Team strategy session.
An objective third party to validate if you are making the right choice for your product portfolio.
Find out how a Japanese pharma company benchmarked the R&D productivity of peer companies for insight into potential patterns and drivers.
Feed industry-leading Evaluate commercial intelligence directly into your internal tools, systems and workflows via data feeds and APIs.
Find out how a major US pharma created a live M&A target screening tool by integrating Evaluate data into a data visualization dashboard.
Customised epidemiology research, forecast modelling, and pricing analysis to inform your product strategy and tactical planning.
Find out how a pharma commercial and finance group established a standard forecasting methodology across an entire business.
Expedite your search and screen efforts to partner, license and sell assets you would otherwise miss.
Find out how a mid-sized pharma BD&L team outsourced their search and screen efforts for a shortlist of assets with potential for licensing.
“ Evaluate Custom Solutions paid careful attention to our report needs, and the after-care service was excellent, so our level of satisfaction was extremely high. It was one of the best services that I have experienced so far. ”
“ I really could not do my job without Evaluate data. You guys make me look good all the time. ”
Evaluate Omnium is the first and only solution on the market that provides a complete, dynamic view of development risk and commercial return, while also addressing the information gaps that lead to unproductive portfolio investments. The result is 4 times greater accuracy when predicting which Phase I assets will reach the market and a 21% accuracy improvement when predicting commercial potential for Phase I assets, compared to calculations made based on industry average benchmarks.